Repositioning Candidate Details
| Candidate ID: | R0234 |
| Source ID: | DB00669 |
| Source Type: | approved; investigational |
| Compound Type: | small molecule |
| Compound Name: | Sumatriptan |
| Synonyms: | (3-[2-(dimethylamino)ethyl]-1H-indol-5-yl)-N-methylmethanesulfonamide; 1-[3-(2-dimethylaminoethyl)-1H-indol-5-yl]-N-methyl-methanesulfonamide; 3-(2-(dimethylamino)ethyl)-N-methyl-1H-indole-5-methanesulfonamide; 3-[2-(dimethylamino)ethyl]-N-methylindole-5-methanesulfonamide |
| Molecular Formula: | C14H21N3O2S |
| SMILES: | CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1 |
| Structure: |
|
| DrugBank Description: | Sumatriptan is a serotonin receptor agonist commonly used to treat migraines and sometimes cluster headaches. Sumatriptan is the first of the triptans and was made available in Europe in 1991 to treat migraines. Sumatriptan was granted FDA approval on 28 December 1992. |
| CAS Number: | 103628-46-2 |
| Molecular Weight: | 295.4 |
| DrugBank Indication: | A combination sumatriptan and tablet is indicated for the treatment of migraines with or without auras in patients 12 years of age and older. Sumatriptan nasal powder, nasal spray, subcutaneous injection, and tablets are indicated to treat migraines with or without auras in adults. One of the subcutaneous formulations of sumatriptan is also indicated to treat cluster headaches in adults, while the other subcutaneous formulation is not. |
| DrugBank Pharmacology: | Sumatriptan constricts cranial blood vessels and prevents the release of vasoactive peptides. The dose of sumatriptan varies widely by route of administration and in most cases, no more than 2 doses should be given daily. Medication overuse headaches may occur in patients who use sumatriptan frequently. |
| DrugBank MoA: | Sumatriptan is an agonist of 5-HT<sub>1B</sub> and 5-HT<sub>1D</sub>. This agonism leads to constriction of cranial blood vessels and inhibits the release of pro-inflammatory neuropeptides. Sumatriptan decreases carotid arterial blood flow, but increases blood flow velocity in the internal carotid artery and middle cerebral artery. |
| Targets: | 5-hydroxytryptamine receptor 1D agonist; 5-hydroxytryptamine receptor 1B agonist; 5-hydroxytryptamine receptor 1F agonist; 5-hydroxytryptamine receptor 1A agonist |
| Inclusion Criteria: | Therapeutic strategy associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs | |
|---|---|---|---|---|---|
| S05 | Anti-inflammatory | inflammatory | Bile acid; TNF-a inhibitor; Dual PPAR-α and -δ agonists; Toll-Like Receptor; (TLR)-4 antagonist; Caspase inhibitor; ASK-1 inhibitor | Ursodeoxycholic Acid; Pentoxifylline; Elafibranor; JKB-121; Emricasan; Selonsertib; | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class |
|---|